Live Breaking News & Updates on Caitlin Kontulis

Stay updated with breaking news from Caitlin kontulis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Phio Pharmaceuticals Announces Dosing of First Patient in

Trial targeting treatment of metastatic melanoma and other solid tumors. ....

United States , Bridge View , Brendan Curti , Robert Bitterman , Caitlin Kontulis , Michael Adams , Robertw Franz , Judith Ann Hartmann , Andrew Weinberg , Providence Cancer Institute Of Oregon , Joseph Health , Earlea Chiles Research Institute , Clinical Research , Providence Cancer Institute In Portland , Laboratory Of Basic Immunology , Phio Pharmaceuticals Corp , Agonox Inc , Phio Pharmaceuticals , Providence Cancer Institute , Adoptive Cell Therapy , Principal Investigator Brendan Curti , Endowed Chair , Research Institute , Judith Ann Hartmann Endowed Chair , Basic Immunology , Cancer Institute ,

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute

MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose pr. ....

United States , Bridge View , Robertw Franz , Robert Bitterman , Brendan Curti , Caitlin Kontulis , Michael Adams , Judith Ann Hartmann , Andrew Weinberg , Earlea Chiles Research Institute , Laboratory Of Basic Immunology , Joseph Health , Clinical Research , Agonox Inc , Providence Cancer Institute Of Oregon , Providence Cancer Institute In Portland , Phio Pharmaceuticals Corp , Phio Pharmaceuticals , Providence Cancer Institute , Adoptive Cell Therapy , Principal Investigator Brendan Curti , Endowed Chair , Research Institute , Judith Ann Hartmann Endowed Chair , Basic Immunology , Cancer Institute ,

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute - Phio Pharma (NASDAQ:PHIO)

MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make ....

United States , Bridge View , Robertw Franz , Michael Adams , Judith Ann Hartmann , Caitlin Kontulis , Andrew Weinberg , Brendan Curti , Robert Bitterman , Providence Cancer Institute Of Oregon , Phio Pharmaceuticals , Phio Pharmaceuticals Corp , Clinical Research , Laboratory Of Basic Immunology , Joseph Health , Providence Cancer Institute In Portland , Agonox Inc , Earlea Chiles Research Institute , Providence Cancer Institute , Adoptive Cell Therapy , Principal Investigator Brendan Curti , Endowed Chair , Research Institute , Judith Ann Hartmann Endowed Chair , Basic Immunology , Cancer Institute ,